Effects and side effects of migraine prophylaxis in children.
children
migraine
prophylaxis
side effects of drugs
treatment
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
29
06
2021
received:
07
03
2021
accepted:
08
12
2021
pubmed:
15
12
2021
medline:
28
5
2022
entrez:
14
12
2021
Statut:
ppublish
Résumé
Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. We aimed to compare the efficacy and side effects of drugs used in migraine prophylaxis, chosen according to the clinical and/or demographic characteristics of the patients. One hundred eighty-six patients aged 6-18 years were evaluated and who were diagnosed with migraine according to The International Classification of Headache Disorders, 3rd edition beta version (ICH-3β). Propranolol, topiramate, flunarizine, and cyproheptadine were given as prophylactic treatment. The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre- and post-treatment values were compared. The median age of the patients was 14 years (range, 6-18 years) and the mean duration of headache was 29.6 ± 21.02 months. The mean PedMIDAS score was 29.9 ± 21.2 before and 14.9 ± 12.5 after treatment. Most reduction in the frequency of attacks was observed in the topiramate group. All four drugs significantly reduced the PedMIDAS score. The most common side effect was palpitations. Significant improvement was found in PedMIDAS scores in all drug groups. Topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety.
Sections du résumé
BACKGROUND
BACKGROUND
Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. We aimed to compare the efficacy and side effects of drugs used in migraine prophylaxis, chosen according to the clinical and/or demographic characteristics of the patients.
METHODS
METHODS
One hundred eighty-six patients aged 6-18 years were evaluated and who were diagnosed with migraine according to The International Classification of Headache Disorders, 3rd edition beta version (ICH-3β). Propranolol, topiramate, flunarizine, and cyproheptadine were given as prophylactic treatment. The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre- and post-treatment values were compared.
RESULTS
RESULTS
The median age of the patients was 14 years (range, 6-18 years) and the mean duration of headache was 29.6 ± 21.02 months. The mean PedMIDAS score was 29.9 ± 21.2 before and 14.9 ± 12.5 after treatment. Most reduction in the frequency of attacks was observed in the topiramate group. All four drugs significantly reduced the PedMIDAS score. The most common side effect was palpitations.
CONCLUSIONS
CONCLUSIONS
Significant improvement was found in PedMIDAS scores in all drug groups. Topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety.
Substances chimiques
Topiramate
0H73WJJ391
Fructose
30237-26-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15094Informations de copyright
© 2021 Japan Pediatric Society.
Références
Abu-arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: A systematic review of population-based studies. Dev. Med. Child Neurol. 2010; 52 (12): 1088-97.
Wober-Bingol C. Epidemiology of migraine and headache in children and adolescents. Curr. Pain Headache Rep. 2013; 17: 341.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. Cephalalgia 2013; 33: 629-808.
Bigal ME, Lipton RB. Migraine chronification. Curr. Neurol. Neurosci. Rep. 2011; 11 (2): 139-48.
Aguggia M, Saracco MG. Pathophysiology of migraine chronification. Neurol. Sci. 2010; 31: S15-7.
Brna PM, Dooley JM. Headaches in the pediatric population. Semin. Pediatr. Neurol. 2006; 13: 222-30.
Hickman C, Lewis KS, Little R, Rastogi RG, Yonker M. Prevention for pediatric and adolescent migraine. Headache 2015; 55 (10): 1371-81.
Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache 2004; 44: 230-7.
Fallah R, Divanizadeh MS, Karimi M, Mirouliaei M, Shamszadeh A. Topiramate and propranolol for prophylaxis of migraine. Indian J. Pediatr. 2013; 80: 920-4.
Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta Neurol. Scand. 1974; 50 (1): 109-15.
Rastogi RG, Borrero-Mejias C, Hickman C, Lewis KS, Little R. Management of episodic migraine in children and adolescents: A practical approach. Curr. Neurol. Neurosci. Rep. 2018; 18 (12): 103.
Lewis D, Winner P, Saper J et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 2009; 123: 924-34.
Winner P, Pearlman EM, Linder SL et al. Topiramate for migraine prevention in children: A randomized, double-blind, place-controlled trial. Headache 2005; 45 (10): 1304-12.
Hershey AD, Powers SW, Vockell ALB, LeCates SL, Segers A, Kabbouche MA. Development of a patient-based grading scale for PedMIDAS. Cephalalgia 2004; 24: 844-9.
Lakshmi CVS, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: A double-blind placebo-controlled trial. J. Child Neurol. 2007; 22: 829-35.
Lu S-R, Fuh J-L, Wang S-J et al. Incidence and risk factors of chronic daily headache in young adolescents: A school cohort study. Pediatrics 2013; 132: 9-16.
Buse DC, Manack AN, Fanning KM et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52 (10): 1456-70.
Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: Results of the chronic daily headache in adolescents study (C-dAS). Headache 2011; 51: 693-706.
Lewis DW, Yonker M, Winner P, Sowell M. The treatment of pediatric migraine. Pediatr. Ann. 2005; 34: 448-60.
Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine. Curr. Pain Headache Rep. 2014; 18: 422.
Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr. Dis. Treat. 2008; 4: 535-48.
Guidetti V, Moscato D, Ottaviano S, Fiorentino D, Fornara R. Flunarizine and migraine in childhood. An evaluation of endocrine function. Cephalalgia 1987; 7: 263-6.
Peer Mohamed B, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years’ experience, with emphasis on its effect in hemiplegic migraine. Dev. Med. Child Neurol. 2012; 54: 274-7.
Kim H, Byun SH, Kim JS et al. Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines. Eur. J. Paediatr. Neurol. 2013; 17: 45-9.
Powers SW, Coffey CS, Chamberlin LA et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N. Engl. J. Med. 2017; 376 (2): 115-24.
Sakulchit T, Meckler GD, Goldman RD. Topiramate for pediatric migraine prevention. Can. Fam. Physician 2017; 63: 529-31.
Ferraro D, Di Trapani G. Topiramate in the prevention of pediatric migraine: Literature review. J. Headache Pain 2008; 9 (3): 147-50.
Bolner A, Riva V, Galloni E, Perini F. Therapeutic Drug Monitoring of Topiramate with a new HPLC Method, SPE Extraction and High Sensitivity Pre-Column Fluorescent Derivatization. Clinical Laboratory 2014; 60 (06/2014). http://dx.doi.org/10.7754/clin.lab.2013.130641
Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics 1987; 79: 593-7.
Macgregor EA, Rosenberg JD, Kurth T. Sex-related differences in epidemiological and clinic-based headache studies. Headache 2011; 51: 843-59.